Cargando…
Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes
The introduction of COVID-19 vaccination passes (VPs) by many countries coincided with the Delta variant fast becoming dominant across Europe. A thorough assessment of their impact on epidemic dynamics is still lacking. Here, we propose the VAP-SIRS model that considers possibly lower restrictions f...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053266/ https://www.ncbi.nlm.nih.gov/pubmed/35603303 http://dx.doi.org/10.1038/s43856-022-00084-w |
_version_ | 1784696961277886464 |
---|---|
author | Krueger, Tyll Gogolewski, Krzysztof Bodych, Marcin Gambin, Anna Giordano, Giulia Cuschieri, Sarah Czypionka, Thomas Perc, Matjaz Petelos, Elena Rosińska, Magdalena Szczurek, Ewa |
author_facet | Krueger, Tyll Gogolewski, Krzysztof Bodych, Marcin Gambin, Anna Giordano, Giulia Cuschieri, Sarah Czypionka, Thomas Perc, Matjaz Petelos, Elena Rosińska, Magdalena Szczurek, Ewa |
author_sort | Krueger, Tyll |
collection | PubMed |
description | The introduction of COVID-19 vaccination passes (VPs) by many countries coincided with the Delta variant fast becoming dominant across Europe. A thorough assessment of their impact on epidemic dynamics is still lacking. Here, we propose the VAP-SIRS model that considers possibly lower restrictions for the VP holders than for the rest of the population, imperfect vaccination effectiveness against infection, rates of (re-)vaccination and waning immunity, fraction of never-vaccinated, and the increased transmissibility of the Delta variant. Some predicted epidemic scenarios for realistic parameter values yield new COVID-19 infection waves within two years, and high daily case numbers in the endemic state, even without introducing VPs and granting more freedom to their holders. Still, suitable adaptive policies can avoid unfavorable outcomes. While VP holders could initially be allowed more freedom, the lack of full vaccine effectiveness and increased transmissibility will require accelerated (re-)vaccination, wide-spread immunity surveillance, and/or minimal long-term common restrictions. |
format | Online Article Text |
id | pubmed-9053266 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-90532662022-05-20 Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes Krueger, Tyll Gogolewski, Krzysztof Bodych, Marcin Gambin, Anna Giordano, Giulia Cuschieri, Sarah Czypionka, Thomas Perc, Matjaz Petelos, Elena Rosińska, Magdalena Szczurek, Ewa Commun Med (Lond) Article The introduction of COVID-19 vaccination passes (VPs) by many countries coincided with the Delta variant fast becoming dominant across Europe. A thorough assessment of their impact on epidemic dynamics is still lacking. Here, we propose the VAP-SIRS model that considers possibly lower restrictions for the VP holders than for the rest of the population, imperfect vaccination effectiveness against infection, rates of (re-)vaccination and waning immunity, fraction of never-vaccinated, and the increased transmissibility of the Delta variant. Some predicted epidemic scenarios for realistic parameter values yield new COVID-19 infection waves within two years, and high daily case numbers in the endemic state, even without introducing VPs and granting more freedom to their holders. Still, suitable adaptive policies can avoid unfavorable outcomes. While VP holders could initially be allowed more freedom, the lack of full vaccine effectiveness and increased transmissibility will require accelerated (re-)vaccination, wide-spread immunity surveillance, and/or minimal long-term common restrictions. Nature Publishing Group UK 2022-03-03 /pmc/articles/PMC9053266/ /pubmed/35603303 http://dx.doi.org/10.1038/s43856-022-00084-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Krueger, Tyll Gogolewski, Krzysztof Bodych, Marcin Gambin, Anna Giordano, Giulia Cuschieri, Sarah Czypionka, Thomas Perc, Matjaz Petelos, Elena Rosińska, Magdalena Szczurek, Ewa Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes |
title | Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes |
title_full | Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes |
title_fullStr | Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes |
title_full_unstemmed | Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes |
title_short | Risk assessment of COVID-19 epidemic resurgence in relation to SARS-CoV-2 variants and vaccination passes |
title_sort | risk assessment of covid-19 epidemic resurgence in relation to sars-cov-2 variants and vaccination passes |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9053266/ https://www.ncbi.nlm.nih.gov/pubmed/35603303 http://dx.doi.org/10.1038/s43856-022-00084-w |
work_keys_str_mv | AT kruegertyll riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT gogolewskikrzysztof riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT bodychmarcin riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT gambinanna riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT giordanogiulia riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT cuschierisarah riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT czypionkathomas riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT percmatjaz riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT peteloselena riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT rosinskamagdalena riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses AT szczurekewa riskassessmentofcovid19epidemicresurgenceinrelationtosarscov2variantsandvaccinationpasses |